![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 02, 2015 7:18:16 AM
NanoViricides Discusses the Strong Effectiveness of Its Anti-Herpes Drug Candidates in a Lethal Animal Model of Dermal Herpes Infection
...
SHELTON, Conn., April 27, 2015 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.
NanoViricides, Inc. recently reported that its anti-Herpes drug candidates demonstrated substantially complete survival of mice that were lethally infected with the HSV-1 H129c strain. In contrast, acyclovir, the standard of care drug, resulted in only a limited survival (less than 58%), even though it was employed at twice the human drug concentration. Further, the survival improvement correlated with the reduction in clinical disease scores, demonstrating significant reduction in disease severity.
These results are very significant considering that topical acyclovir in the form of a cream as well as an ointment are approved for the treatment of cold sores.
Our strong anti-herpes nanoviricide® drug candidates are capable of reaching approval as drug for topical use against herpes cold sores, the Company believes, based on these datasets. Further drug development is necessary towards the goal of drug approval.
The Company intends to meet with its FDA advisory consulting group, namely, Biologics Consulting Group, Inc., to chart out the path towards approval. In addition, the Company intends to engage a Contract Research Organization (CRO) for further development of a topical anti-herpes drug into the regulatory approval pathway for US FDA as well as internationally.
"A rapid drug approval process is possible for our anti-herpes nanoviricide® topical skin treatment," said Eugene Seymour, MD, MPH, "We intend to investigate the regulatory pathway and intend to put our anti-herpes drug candidates into the approval process as soon as feasible."
"The pace of development of our broad drug pipeline is now accelerating due to the strong financing we have been able to raise concomitant with our up-listing to the NYSE-MKT exchange," said Anil R. Diwan, PhD, President.
In another news, the Company reports that the process of commissioning of its new facility in Shelton is on course. Our Bio-Analysis Group has already moved operations to the new facility. Large Scale Chemistry Group is completing the necessary modifications to the facility to enable large scale production processes. Various laboratory instruments are being installed by vendors under warranty programs for installation qualification and operational qualification.
http://www.prnewswire.com/news-releases/nanoviricides-discusses-the-strong-effectiveness-of-its-anti-herpes-drug-candidates-in-a-lethal-animal-model-of-dermal-herpes-infection-300072282.html
![](http://3dprint.com/wp-content/uploads/2015/03/b33.png)
So they have a warranty program from the vendor and I speculate the scale up will not be as laborious as it has been for months!
===========================================
"It is not easy to convey, unless one has experienced it, the dramatic feeling of sudden enlightenment that floods the mind when the right idea finally clicks into place. One immediately sees how many previously puzzling facts are neatly explained by the new hypothesis. One could kick oneself for not having the idea earlier, it now seems so obvious. Yet before, everything was in a fog." ~ Francis Crick, What Mad Pursuit
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM